Minimum clinically important difference in Quantitative Lung Fibrosis score associated with all-cause mortality in idiopathic pulmonary fibrosis: subanalysis from two phase II trials of pamrevlumab

By sjmartinez • May 13, 2025

Kim GH, Zhang X, Brown MS, Poole L, Goldin J. Minimum clinically important difference in Quantitative Lung Fibrosis score associated with all-cause mortality in idiopathic pulmonary fibrosis: subanalysis from two phase II trials of pamrevlumab. BMJ Open. 2025 May 12;15(5):e094559. doi: 10.1136/bmjopen-2024-094559. PMID: 40355288.

Tags: Chest imaging, Computed tomography, interstitial lung disease, Patient reported outcome measures, Publications, Pulmonary Disease, Pulmonary, Critical Care & Sleep Medicine, QUALITATIVE RESEARCH

Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis

Kishan AU, Sun Y, Parker CC, Sargos P, Sydes MR, Chabaud S, Brihoum M, Kalbasi TR, Steinberg ML, Valle LF, Taparra K, Shoag JE, Garcia[...]

Rebuilding the foundation: recommendations from the Summit to Revitalize Primary Care (Rev PC)

Summit to Revitalize Primary Care Writing Committee*; Jerant A, Kravitz RL, Fenton JJ, Lyles CR, Grumbach K, Henderson MC, Ritley D, Brandt M, Cohen D,[...]

Hepatocyte growth factor may contribute to male protection against pulmonary arterial hypertension

Medzikovic L, Ruffenach G, Dehghanitafti A, Wong B, Ryder A, Hatamnejad MR, Sun W, Esdin L, Eghbali J, Brownstein A, Razee A, Umar S, Hong[...]